Indivior Reports Q3 2026 Results and Confirms Imminent Merger with Supernus

Indivior announced its third-quarter 2026 results and confirmed that its all-stock merger with Supernus Pharmaceuticals is scheduled to close on November 2, 2026. The combined CNS-focused biopharmaceutical company will operate as Supernus, Inc. and trade on the Nasdaq Global Select Market under ticker SUPN beginning November 3. Indivior said the merger completes the final phase of its “Indivior Action Agenda.”